Abiopharma

HUNTINGTON INGALLS INDUSTRIES, INC. (HII) Reports the reporting period Financial Results HUNTINGTON INGALLS INDUSTRIES, INC. (HII) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 748
• Net Income: 149
• EPS: 3.79
• Cash and equivalents: 216
  • anticipated by our forward-looking statements, which include, but are not limited to:•our dependence on the U.S. Government for substantially all of our business;•significant delays or reductions in appropriations for our programs and/or changes in customer priorities and requirements (including government budgetary constraints, government shutdowns, shifts in defense spending, and changes in customer short-range and long-range plans);•our ability to estimate our future contract costs, including cost increases due to inflation, labor challenges, changes in trade policy, or other factors and our efforts to recover or offset such costs and/or changes in estimated contract costs, and perform our contracts effectively;•changes in business practices, procurement processes and government regulations, including changes through executive orders, contract terms, or other policies or practices applicable to our industry, and our ability to comply with such requirements;•adverse economic conditions in the United States and globally;•our level of indebtedness and ability to service our indebtedness;•our ability to deliver our products and services at an affordable life cycle cost and compete within our markets;•our ability to attract, retain, and train a qualified workforce;•subcontractor and supplier performance and the availability and pricing of raw materials and components;•our ability to execute our strategic plan, including with respect to share repurchases, dividends, capital expenditures, and strategic acquisitions;•investigations, claims, disputes, enforcement actions, litigation (including criminal, civil, and administrative), and/or other legal proceedings, and improper conduct of employees, agents, subcontractors, suppliers, business partners, or joint ventures in which we participate, including the impact on our reputation or ability to do business; •changes in key estimates and assumptions regarding our pension and retiree health care costs;•security threats, including cyber security threats, and related disruptions;•natural and environmental disasters and political instability;•health epidemics, pandemics and similar outbreaks; and•other risk factors discussed herein and in our other filings with the SEC.There may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business, and we undertake no obligation to update or revise any forward-looking statements. You should not place undue reliance on any forward-looking statements that we may make.This release also contains non-GAAP financial measures and includes a GAAP reconciliation of these financial measures. Non-GAAP financial measures should not be construed as being more important than comparable GAAP measures. HII4101